Patent EP-1910383-B1 (EP)
Inventor: SILVESTRI ROMANO
IPC: A61P35/02
Filed: 2006-05-26
Granted: 2009-09-16
Abstract: The invention concerns benzodiazepine derivatives of formula wherein Y it is SO<SUB>2 </SUB>or NR, wherein R is H or C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl; X is H, C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, -CO, -SO, -SO<SUB>2</SUB>, or -CO-R<SUB>2</SUB>, SO-R<SUB>2</SUB>, SO<SUB>2</SUB>-R<SUB>2</SUB>, wherein R<SUB>2 </SUB>is selected from H, C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, (C<SUB>3-C</SUB><SUB>8 </SUB>cycloalkyl) C<SUB>0</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkynyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkoxycarbonyl, phenyl, benzyl, naphtyl, biphenyl, or heterocycle, each para-, meta- or ortho-substituted independently of each other with 0 to 3 substituents selected from halogen, -CN, -NH<SUB>2</SUB>, -OH, -NO<SUB>2</SUB>, COOR<SUB>3</SUB>, wherein R<SUB>3 </SUB>is selected from H, C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, (C<SUB>3</SUB>-C<SUB>8 </SUB>cycloalkyl) C<SUB>0</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, C<SUB>2</SUB>-C<SUB>6 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkynyl, or C<SUB>2</SUB>-C<SUB>6 </SUB>alkoxy carbonyl; phenyl, benzyl, naphtyl, biphenyl, or heterocycle n is 0-6; R<SUB>4 </SUB>is selected from H, OH, COOH, CN, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, C<SUB>2</SUB>-C<SUB>6 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkynyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkoxycarbonyl, -CO, -SO, -SO<SUB>2</SUB>, or -CO-R<SUB>5</SUB>, SO-R<SUB>5</SUB>, SO<SUB>2</SUB>-R<SUB>2</SUB>, -OCO-R<SUB>5</SUB>, OSO-R<SUB>5</SUB>, SO<SUB>2</SUB>-R<SUB>5</SUB>, COOR<SUB>5</SUB>, SOOR<SUB>5</SUB>, SO<SUB>2</SUB>OR<SUB>5</SUB>, NHR<SUB>5</SUB>, NHCOR<SUB>5</SUB>, NHSO<SUB>2</SUB>R<SUB>5</SUB>, SR<SUB>5</SUB>, SCOR<SUB>5</SUB>, wherein R<SUB>5 </SUB>is selected from H, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, C<SUB>2</SUB>-C<SUB>6 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkynyl, or C<SUB>2</SUB>-C<SUB>6 </SUB>alkoxycarbonyl, phenyl, benzyl, naphtyl, biphenyl, or heterocycle, each para-, meta- or ortho-substituted independently of each other with 0 to 3 substituents selected from halogen, -CN, -NH<SUB>2</SUB>, <SUB>OH, -NO</SUB><SUB>2</SUB>, COOR<SUB>5'</SUB>, wherein R<SUB>5 </SUB>is selected from H, C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, (C<SUB>3</SUB>-C<SUB>8 </SUB>cycloalkyl) C<SUB>0</SUB>-C<SUB>6 </SUB>alkyl, phenyl, benzyl, naphtyl, biphenyl, or heterocycle, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, C<SUB>2</SUB>-C<SUB>6 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkynyl, or C<SUB>2</SUB>-C<SUB>6 </SUB>alkoxy carbonyl; R<SUB>6 </SUB>and R<SUB>7 </SUB>independently of each other are selected from the group consisting of H, OH, halogen, CN, NH<SUB>2</SUB>, NO<SUB>2</SUB>, COOR<SUB>3</SUB>, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, C<SUB>2</SUB>-C<SUB>6 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkynyl, and C<SUB>2</SUB>-C<SUB>6 </SUB>alkoxy carbonyl; R<SUB>3 </SUB>is H, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl C<SUB>2</SUB>-C<SUB>6 </SUB>alkenyl, C<SUB>2</SUB>-C<SUB>6 </SUB>alkynyl or physiologically acceptable salts and uses thereof in medical field, particularly as anti-tumoral agents.